Significance of Newly Approved IPX203 for Parkinson Disease

[Farooqji]

Earlier this month, the FDA approved Amneal Pharmaceuticals’ investigational agent IPX203, an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules, as a treatment for patients with Parkinson disease (PD). Marketed as Crexont, the therapy is an oral formulation CD/LD which includes immediate-release granules as well as extended-release pellets. In its announcement, Amneal noted it expects the oral treatment to be available to patients in the United States in September 2024.

neurologylive.com/view/sign...

[Buckholt]

So now it’s about the cost. If people can’t afford it or if in the UK the cost benefit analysis means it cannot be universally prescribed, then ………..

[Smittybear7]

who would it be available to thanks for sharing

[Grey_Area]

I posted this info in another forum. The drug is also known as "Crexont".

What I can't find is what's so different about it compared to other controlled release L-Dopa products like Sinemet CR

Reading the info you'd be forgiven for thinking this was the first controlled release L-Dopa ever. In particular why have they benchmarked it against standard release rather than another CR product?

[JPeezy]

sounds just like Rytary

[rebtar]

Very strange. I searched for Crexont vs Rytary, an article apeared, i could see the furst paragraph, but i couldnt get access. When i tried a second time, instead of the article, it said "page doesn't exist".

[rebtar]

pdexpertinstitute.com/exten...

[Gioc in reply to rebtar]

In my opinion, these pellet medications always have a wide standard deviation (SD) that is not shown in the above graphs (figure 3; there should be vertical lines above each point). It would have been important to know this SD data in order to understand if the response to the medication is the same for everyone or subjective.

[rebtar in reply to Gioc]

👍